IL6 and COVID-19: Severe COVID-19 patients also showed increased IL-6, IL-1β, and IFN-γ.23 It is worthy of studying whether blockade of IL-6 or IL-1β, which is currently under clinical trials, would reduce cardiac injury through inhibition of CD8+ T cell-macrophage infiltration and overactivation.